Terminated NA INTERVENTIONAL 1-arm NCT01502228

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Sponsor: Indiana University

Interventions 150-Water 62Cu-ethylglyoxal bis Positron Emission Tomography Sunitinib

Updated 8 times since 2017 Last updated: Feb 22, 2019 Started: Oct 31, 2011 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

No further funding

Other terminated trials from Indiana University

See all terminations from Indiana University

Other Renal Cell Carcinoma trials with similar outcome

Browse all Renal Cell Carcinoma trials

Listed as NCT01502228, this NA trial focuses on Renal Cell Carcinoma and remains terminated or withdrawn. Sponsored by Indiana University, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Apr 2019 — Jan 2021 [monthly]

Terminated NA
Jun 2018 — Apr 2019 [monthly]

Terminated NA

▶ Show 3 earlier versions

May 2017 — Jun 2018 [monthly]

Terminated NA
Feb 2017 — May 2017 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States